pharmacie et médicaments – Réduction du plafond des remises sur les médicaments génériques et biosimilaires

This written question asks about proposed changes to the maximum rebates allowed for generic and biosimilar medicines. The aim is to understand the potential impact of these changes on the pharmaceutical market and patient access to affordable treatments. The question concerns the pharmaceutical industry, specifically manufacturers of generic and biosimilar drugs. It seeks clarification on how the proposed rebate cap will affect pricing strategies and the availability of these essential medicines.